
DBV Technologies is a French biotechnology company that focuses on developing treatments for food allergies. Founded in 2002 by Pierre-Henri Benhamou, DBV Technologies is headquartered in Montrouge, France.
The company's innovative approach to treating food allergies involves the use of a patch called Viaskin, which is designed to desensitize patients to specific allergens. DBV Technologies has a robust pipeline of products in development, targeting various food allergies.
One of the company's most notable products is Viaskin Peanut, a patch designed to treat peanut allergy. This product has shown promising results in clinical trials, with a significant reduction in allergic reactions.
Check this out: Sumitomo Precision Products
Financials and Funding
DBV Technologies has raised a total funding of $68.9M over 8 rounds, with its first funding round taking place on January 23, 2006. This shows that the company has a history of securing funding to support its growth.
Its most recent funding round was on April 7, 2025, where it raised $307M in a post-IPO round. This is a significant boost to the company's financial situation.
Explore further: Technology Startup Funding
DBV Technologies has 18 institutional investors, including Sofinnova Partners, Apax, and ALK-Abello. These investors have provided crucial support to the company's growth.
The company's financial position is a bit precarious, with an EBITDA loss of $96.59M and a negative cash flow. This means that DBV Technologies is bleeding money and needs a lifeline to stay afloat.
Despite this, the company has a current cash position of $46.44M, down from $66.21M earlier. This shows that the company's cash flow is still a concern.
DBV Technologies' balance sheet displays a long-term debt of $7.03M and an equity value of $63.11M. This means that the company is carrying a significant amount of debt.
Here's a summary of DBV Technologies' funding rounds:
The company's cash burn is still a concern, with a return on equity (ROE) of -109.85%. This means that DBV Technologies is struggling to generate profits from its investments.
Regulatory and Market Impact
DBV Technologies' regulatory journey has been a game-changer for the company's stock performance. A significant boost in shares was observed following a promising outcome from the FDA's assessment of their VITESSE Phase 3 study.
The FDA's nod has cleared substantial safety hurdles for the Viaskin Peanut Patch, making it a pivotal step in their plan to submit a biologics license application in the first half of 2026. This has allowed DBV Technologies to navigate the licensing maelstrom with more certainty.
The company's stock has seen a 9.2% surge, emerging as a leader among European equities trading in the US. This surge is a testament to the FDA's endorsement, which is often a golden ticket for biotech valuations.
The Viaskin Peanut Patch's revolutionary approach to treating allergies has eradicated the need for additional trials, saving time and expenses. This has reinforced confidence in DBV Technologies' methodology, a claim to fame that may resonate across investment channels.
DBV Technologies' recent negotiation on safety exposure data requirements with the FDA has also advanced plans for market release by a full year. This is a significant development, reflecting the company's progress in their regulatory journey.
Here are some key takeaways from DBV Technologies' regulatory and market impact:
- 9.2% surge in stock performance following FDA's assessment of VITESSE Phase 3 study
- Clearance of substantial safety hurdles for Viaskin Peanut Patch
- Advancement of plans for market release by a full year
- Submission of biologics license application in the first half of 2026
Despite these advancements, DBV Technologies is mired in financial challenges, with considerable cash burn raising concerns over their ability to remain viable without further financial support.
Products and Partnerships
DBV Technologies is exploring strategic partnerships to bolster its cash reserves and maintain technological strides. This approach is a tactical option to mitigate fears about solvency and operating capital.
An infusion of capital from credible partners will solidify the company's market footprint and kindle the light for future ventures. This is a crucial step in evolving beyond its reliant strategy.
Continual FDA praise has allowed DBV Technologies to navigate regulatory halls with ease, giving them the confidence to pursue new opportunities.
Products in Development
DBV Technologies is working on several innovative products to tackle common allergies. One of these products is Viaskin Peanuts, which is currently seeking a license from the FDA for treating peanut allergies.
Viaskin Milk is another product in development, designed for children with cow's milk allergies. It's currently undergoing a 36-month testing phase.
Research is also underway for Viaskin Egg, which aims to address egg allergies. This product is still in the pre-clinical research phase.
If this caught your attention, see: Müller Milk & Ingredients
Rescue through Partnerships
DBV Technologies faces a critical juncture where seeking strategic alliances becomes unavoidable.
Partnering with larger financial or pharmaceutical bodies can provide an infusion of capital, solidifying the company's market footprint and paving the way for future ventures.
This approach can help mitigate fears about solvency and operating capital, allowing DBV Technologies to maintain its technological strides.
An influx of capital from credible partners can kindle the light for future endeavors, propelling the company beyond its current reliant strategy.
Continual FDA praise suggests that regulatory hurdles won't hinder DBV Technologies' journey, even as it evolves through partnerships.
By forging strategic alliances, DBV Technologies can bolster its cash reserves and navigate the challenging landscape ahead.
Investor and Competitor Information
DBV Technologies has received significant investment from various sources, including the Bill and Melinda Gates Foundation, which has provided funding for the company's research and development efforts.
The company's main competitor in the allergy immunotherapy market is ALK-Abelló, a Danish biotech company that offers a similar product called Grazax.
DBV Technologies has a strong patent portfolio, with multiple patents granted for its epicutaneous immunotherapy technology.
ALK-Abelló's Grazax has been approved in several countries, including the US, EU, and Australia, and is available by prescription only.
DBV Technologies has a strong presence in the US market, with its product Viaskin being approved by the FDA in 2016.
The company has a significant market share in the allergy immunotherapy market, with its Viaskin product being used by thousands of patients worldwide.
Filings
DBV Technologies has a history of filing various documents with the regulatory bodies. The company has filed a total of 13 documents between May 6, 2025, and June 20, 2025.
Some of the notable filings include a Major Shareholding Notification on June 17, 2025, and another on June 20, 2025. These filings were both in French and had sizes of 107.2 KB and 124.2 KB, respectively.
DBV Technologies has also filed an Earnings Release on June 12, 2025, which was in English and had a size of 275.8 KB. This release was accompanied by a Regulatory News Service filing in French with a size of 269.7 KB.

The company has been transparent about its voting results and voting rights, filing multiple documents on this topic between May 6, 2025, and June 11, 2025. These filings included information in both English and French.
Here is a list of the filings by date:
Frequently Asked Questions
Who is the CEO of DBV Technologies?
DBV Technologies is led by CEO Daniel Tassé, who drives the company's mission to deliver solutions for patients with severe food allergy and other immunological diseases.
What is dBV inc?
DBV Technologies is a global biopharmaceutical company pioneering epicutaneous immunotherapy for food allergies. We're on a mission to make allergy treatment safer and more effective.
Featured Images: pexels.com


